Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke

Translational Stroke Research

Volumn 7, Issue 3, 2016, Pages 209-219

  Liu, Hui ^a,b   Wang, Yi ^a   Xiao, Yunqi ^a   Hua, Zichun ^b   Cheng, Jian ^a,b   Jia, Jia ^c  

^a SOOCHOW UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Blood brain barrier; Cerebral ischemia; Hemorrhage; Hydrogen sulfide; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; EVANS BLUE; GELATINASE B; HEMOGLOBIN; HYDROGEN SULFIDE; PROTEIN KINASE B; VASCULOTROPIN; FIBRINOLYTIC AGENT; GLUCOSE; NEUROPROTECTIVE AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; CAPILLARY ENDOTHELIAL CELL; CONTINUOUS INFUSION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL STROKE; HEMOGLOBIN DETERMINATION; IN VITRO STUDY; MALE; MEMBRANE DAMAGE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REOXYGENATION; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; CELL CULTURE; CEREBRAL HEMORRHAGE; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; HYPOXIA; METABOLISM; NEUROLOGIC EXAMINATION; SEVERITY OF ILLNESS INDEX; STROKE;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN EDEMA; BRAIN INFARCTION; CELLS, CULTURED; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FIBRINOLYTIC AGENTS; GLUCOSE; HYDROGEN SULFIDE; HYPOXIA; MALE; MATRIX METALLOPROTEINASE 9; MICE; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; SEVERITY OF ILLNESS INDEX; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84962262022     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-016-0459-5     Document Type: Article

References (46)

1. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29. doi:10.1056/NEJMoa0804656.
2. Hafez S, Hoda MN, Guo X, Johnson MH, Fagan SC, Ergul A. Comparative analysis of different methods of ischemia/reperfusion in hyperglycemic stroke outcomes: interaction with tPA. Transl Stroke Res. 2015;6(3):171–80. doi:10.1007/s12975-015-0391-0.
3. Wardlaw JM, Sandercock PA, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke J Cereb Circ. 2003;34(6):1437–42. doi:10.1161/01.STR.0000072513.72262.7E.
4. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003;4(5):399–415. doi:10.1038/nrn1106.
5. Dijkhuizen RM, Asahi M, Wu O, Rosen BR, Lo EH. Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model. Stroke J Cereb Circ. 2002;33(8):2100–4.
6. Kastrup A, Groschel K, Ringer TM, Redecker C, Cordesmeyer R, Witte OW, et al. Early disruption of the blood–brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke. Stroke J Cereb Circ. 2008;39(8):2385–7. doi:10.1161/STROKEAHA.107.505420.
7. Wang L, Fan W, Cai P, Fan M, Zhu X, Dai Y, et al. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice. Ann Neurol. 2013;73(2):189–98. doi:10.1002/ana.23762.
8. Won S, Lee JH, Wali B, Stein DG, Sayeed I. Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2014;34(1):72–80. doi:10.1038/jcbfm.2013.163.
9. Oesterhelweg L, Puschel K. “Death may come on like a stroke of lightening”: phenomenological and morphological aspects of fatalities caused by manure gas. Int J Legal Med. 2008;122(2):101–7. doi:10.1007/s00414-007-0172-8.
10. Wallace JL, Wang R. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov. 2015;14(5):329–45. doi:10.1038/nrd4433.
11. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A. 2007;104(39):15560–5. doi:10.1073/pnas.0705891104.
12. Zhu YZ, Wang ZJ, Ho P, Loke YY, Zhu YC, Huang SH, et al. Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats. J Appl Physiol. 2007;102(1):261–8. doi:10.1152/japplphysiol.00096.2006.
13. Nicholson CK, Lambert JP, Molkentin JD, Sadoshima J, Calvert JW. Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure. Arterioscler Thromb Vasc Biol. 2013;33(4):744–51. doi:10.1161/ATVBAHA.112.300484.
14. Bos EM, Wang R, Snijder PM, Boersema M, Damman J, Fu M, et al. Cystathionine gamma-Lyase protects against renal ischemia/reperfusion by modulating oxidative stress. J Am Soc Nephrol. 2013;24(5):759–70. doi:10.1681/ASN.2012030268.
15. Hunter JP, Hosgood SA, Patel M, Rose R, Read K, Nicholson ML. Effects of hydrogen sulphide in an experimental model of renal ischaemia-reperfusion injury. Br J Surg. 2012;99(12):1665–71. doi:10.1002/bjs.8956.
16. Suzuki K, Olah G, Modis K, Coletta C, Kulp G, Gero D, et al. Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl Acad Sci U S A. 2011;108(33):13829–34. doi:10.1073/pnas.1105121108.
17. Wen YD, Wang H, Kho SH, Rinkiko S, Sheng X, Shen HM, et al. Hydrogen sulfide protects HUVECs against hydrogen peroxide induced mitochondrial dysfunction and oxidative stress. PLoS One. 2013;8(2), e53147. doi:10.1371/journal.pone.0053147.
18. Cui Y, Duan X, Li H, Dang B, Yin J, Wang Y, et al. Hydrogen sulfide ameliorates early brain injury following subarachnoid hemorrhage in rats. Mol Neurobiol. 2015. doi:10.1007/s12035-015-9304-1.
19. Wang Y, Jia J, Ao G, Hu L, Liu H, Xiao Y, et al. Hydrogen sulfide protects blood–brain barrier integrity following cerebral ischemia. J Neurochem. 2014;129(5):827–38. doi:10.1111/jnc.12695.
20. Zhu W, Casper A, Libal NL, Murphy SJ, Bodhankar S, Offner H, et al. Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke. Transl Stroke Res. 2015;6(1):60–8. doi:10.1007/s12975-014-0373-7.
21. Suenaga J, Hu X, Pu H, Shi Y, Hassan SH, Xu M, et al. White matter injury and microglia/macrophage polarization are strongly linked with age-related long-term deficits in neurological function after stroke. Exp Neurol. 2015;272:109–19. doi:10.1016/j.expneurol.2015.03.021.
22. Dong W, Qi Z, Liang J, Shi W, Zhao Y, Luo Y, et al. Reduction of zinc accumulation in mitochondria contributes to decreased cerebral ischemic injury by normobaric hyperoxia treatment in an experimental stroke model. Exp Neurol. 2015;272:181–9. doi:10.1016/j.expneurol.2015.04.005.
23. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood–brain barrier integrity during ischemic stroke. Nat Med. 2008;14(7):731–7. doi:10.1038/nm1787.
24. Won SJ, Tang XN, Suh SW, Yenari MA, Swanson RA. Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by increasing superoxide production. Ann Neurol. 2011;70(4):583–90. doi:10.1002/ana.22538.
25. Poppe AY, Majumdar SR, Jeerakathil T, Ghali W, Buchan AM, Hill MD, et al. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care. 2009;32(4):617–22. doi:10.2337/dc08-1754.
26. Jin Q, Cheng J, Liu Y, Wu J, Wang X, Wei S, et al. Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. Brain Behav Immun. 2014;40:131–42. doi:10.1016/j.bbi.2014.03.003.
27. Mao L, Jia J, Zhou X, Xiao Y, Wang Y, Mao X, et al. Delayed administration of a PTEN inhibitor BPV improves functional recovery after experimental stroke. Neuroscience. 2013;231:272–81. doi:10.1016/j.neuroscience.2012.11.050.
28. Zhu W, Libal NL, Casper A, Bodhankar S, Offner H, Alkayed NJ. Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke. Transl Stroke Res. 2014;5(5):612–7. doi:10.1007/s12975-014-0348-8.
29. Kilic E, Kilic U, Wang Y, Bassetti CL, Marti HH, Hermann DM. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF’s neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J Off Publ Fed Am Soc Exp Biol. 2006;20(8):1185–7. doi:10.1096/fj.05-4829fje.
30. Geng Y, Li E, Mu Q, Zhang Y, Wei X, Li H, et al. Hydrogen sulfide inhalation decreases early blood–brain barrier permeability and brain edema induced by cardiac arrest and resuscitation. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2015;35(3):494–500. doi:10.1038/jcbfm.2014.223.
31. Kamat PK, Kyles P, Kalani A, Tyagi N. Hydrogen sulfide ameliorates homocysteine-induced Alzheimer’s disease-like pathology, blood–brain barrier disruption, and synaptic disorder. Mol Neurobiol. 2015. doi:10.1007/s12035-015-9212-4.
32. Gu X, Zhu YZ. Therapeutic applications of organosulfur compounds as novel hydrogen sulfide donors and/or mediators. Expert Rev Clin Pharmacol. 2011;4(1):123–33. doi:10.1586/ecp.10.129.
33. Whiteman M, Winyard PG. Hydrogen sulfide and inflammation: the good, the bad, the ugly and the promising. Expert Rev Clin Pharmacol. 2011;4(1):13–32. doi:10.1586/ecp.10.134.
34. Li L, Whiteman M, Guan YY, Neo KL, Cheng Y, Lee SW, et al. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation. 2008;117(18):2351–60. doi:10.1161/CIRCULATIONAHA.107.753467.
35. Marutani E, Kosugi S, Tokuda K, Khatri A, Nguyen R, Atochin DN, et al. A novel hydrogen sulfide-releasing N-methyl-D-aspartate receptor antagonist prevents ischemic neuronal death. J Biol Chem. 2012;287(38):32124–35. doi:10.1074/jbc.M112.374124.
36. Lee M, Tazzari V, Giustarini D, Rossi R, Sparatore A, Del Soldato P, et al. Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease. J Biol Chem. 2010;285(23):17318–28. doi:10.1074/jbc.M110.115261.
37. Ukai Y, Taniguchi N, Takeshita K, Kimura K, Enomoto H. Chronic anethole trithione treatment enhances the salivary secretion and increases the muscarinic acetylcholine receptors in the rat submaxillary gland. Arch Int Pharmacodyn Ther. 1984;271(2):206–12.
38. Xie H, Xu Q, Jia J, Ao G, Sun Y, Hu L, et al. Hydrogen sulfide protects against myocardial ischemia and reperfusion injury by activating AMP-activated protein kinase to restore autophagic flux. Biochem Biophys Res Commun. 2015;458(3):632–8. doi:10.1016/j.bbrc.2015.02.017.
39. An J, Zhang C, Polavarapu R, Zhang X, Zhang X, Yepes M. Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood. 2008;112(7):2787–94. doi:10.1182/blood-2008-02-141630.
40. Zhang ZG, Zhang L, Tsang W, Soltanian-Zadeh H, Morris D, Zhang R, et al. Correlation of VEGF and angiopoietin expression with disruption of blood–brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2002;22(4):379–92. doi:10.1097/00004647-200204000-00002.
41. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–65.
42. Qu K, Chen CP, Halliwell B, Moore PK, Wong PT. Hydrogen sulfide is a mediator of cerebral ischemic damage. Stroke J Cereb Circ. 2006;37(3):889–93. doi:10.1161/01.STR.0000204184.34946.41.
43. Hu LF, Lu M, Hon Wong PT, Bian JS. Hydrogen sulfide: neurophysiology and neuropathology. Antioxid Redox Signal. 2011;15(2):405–19. doi:10.1089/ars.2010.3517.
44. Tao BB, Liu SY, Zhang CC, Fu W, Cai WJ, Wang Y, et al. VEGFR2 functions as an H2S-targeting receptor protein kinase with its novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch for hydrogen sulfide actions in vascular endothelial cells. Antioxid Redox Signal. 2013;19(5):448–64. doi:10.1089/ars.2012.4565.
45. Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, Mariani JN, et al. Astrocyte-derived VEGF-A drives blood–brain barrier disruption in CNS inflammatory disease. J Clin Invest. 2012;122(7):2454–68. doi:10.1172/JCI60842.
46. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, et al. VEGF enhances angiogenesis and promotes blood–brain barrier leakage in the ischemic brain. J Clin Invest. 2000;106(7):829–38. doi:10.1172/JCI9369.